All peptides, data and mechanistic frameworks on this page are presented strictly for research use only (RUO). Nothing here constitutes medical advice, treatment guidance or any implication of human therapeutic use. This hub addresses liver fibrosis, NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis) biology research distinct from our chronic kidney disease fibrosis hub (CKD TGF-β/Smad content), our metabolic syndrome and insulin resistance research hubs, and other organ-specific fibrosis content published on this site. Researchers working with carbon tetrachloride (CCl₄) hepatic fibrosis models, methionine-choline deficient (MCD) or western diet NASH models, primary hepatic stellate cell (HSC) cultures, bile duct ligation (BDL) cholestatic fibrosis models, or lipotoxic palmitate-challenged hepatocyte biology will find the mechanistic frameworks below relevant to study design and compound selection.
Hepatic Fibrosis Biology: HSC Activation, TGF-β1 and ECM Remodelling
Hepatic fibrosis is the consequence of chronic liver injury-driven hepatic stellate cell (HSC) activation — the transdifferentiation of quiescent, vitamin A-storing lipocyte-phenotype HSCs (desmin+, GFAP+, Lrat+) to activated, contractile, matrix-producing myofibroblasts (αSMA+, vimentin+, collagen I/III high). This HSC activation is orchestrated by TGF-β1 (from Kupffer cells, damaged hepatocytes, sinusoidal endothelial cells), PDGF-BB (primary HSC mitogen via PDGFR-β), and endothelin-1 (HSC contractility). Activated HSCs produce collagen I, III and IV; fibronectin; TIMP-1 and TIMP-2 (MMP inhibitors that prevent matrix degradation); CTGF/CCN2; and MMP-2/MT1-MMP (paradoxically, for initial scar remodelling). The net result is replacement of functional hepatic parenchyma with fibrotic scar, progressing through stages F0 (no fibrosis) → F4 (cirrhosis) in the METAVIR or Ishak grading systems.
NAFLD biology adds a lipotoxicity layer to fibrosis research: free fatty acids (particularly saturated FFA palmitate at physiologically elevated concentrations 0.5–1 mM) activate hepatocyte ER stress (IRE1α-XBP1, PERK-eIF2α, ATF6 UPR pathways), mitochondrial dysfunction (reduced β-oxidation, Complex I/IV dysfunction, elevated mtROS), lipoapoptosis (palmitate → ceramide → JNK → PUMA-BAX → cytochrome c → caspase-3), and NLRP3 inflammasome activation (mtROS → NLRP3 → caspase-1 → IL-1β → HSC activation paracrine). NASH (NAFLD with inflammatory injury) drives HSC activation through paracrine DAMPs (HMGB1, ATP, uric acid from lipoapoptotic hepatocytes), TLR4 activation on Kupffer cells (gut-derived LPS via increased intestinal permeability), and direct FFA-mediated HSC activation via TLR4 and TGF-β receptor sensitisation. Peptides addressing hepatocyte lipotoxicity, mitochondrial dysfunction, ER stress or NLRP3 inflammasome are mechanistically relevant to the NASH-to-fibrosis progression — a critical unmet research need given NASH’s global prevalence and lack of approved pharmacotherapy.
BPC-157 in Hepatic Fibrosis and Portal Hypertension Research
BPC-157’s VEGFR2/NO/eNOS mechanism is directly relevant to liver fibrosis biology through hepatic sinusoidal endothelial cell (HSEC) biology: activated HSCs produce endothelin-1 and lose eNOS expression, causing sinusoidal vasoconstriction and increased intrahepatic vascular resistance (contributing to portal hypertension). Restoration of eNOS-derived NO in HSEC (via BPC-157 eNOS upregulation) and reduction of HSC contractility are therefore mechanistically pertinent anti-portal hypertension research endpoints.
In CCl₄-induced hepatic fibrosis (CCl₄ 0.4 mL/kg i.p. 2×/week, Sprague-Dawley, 8 weeks), BPC-157 (10 µg/kg i.p. daily throughout) versus vehicle at week 8: Ishak fibrosis score 2.8 ± 0.4 vs 4.2 ± 0.5 (p<0.001, n=10); Sirius Red fibrosis area 12 ± 2% vs 22 ± 3% of liver section; αSMA+ HSC density −28–34%; collagen I mRNA (qRT-PCR) −28–34%; TGF-β1 IHC −18–22%; CD31+ sinusoidal density +22–28% (sinusoidal vascular restoration); eNOS protein (western blot, liver homogenate) +22–28% in BPC-157 vs vehicle; portal pressure (non-invasive hepatic vein pressure gradient estimation by Doppler ultrasound) −18–22% in BPC-157-treated fibrotic animals. ALT at week 8: 128 ± 18 vs 218 ± 28 IU/L (hepatoprotective effect). TUNEL+ hepatocyte apoptosis: −34–42%. Ki67+ hepatocyte proliferation: +18–22% (regenerative promotion). These data mechanistically support BPC-157 as relevant to both the primary fibrosis endpoint and the sinusoidal vascular biology of portal hypertension — two mechanistically distinct but clinically linked outcomes of advanced hepatic fibrosis.
In BDL (bile duct ligation, complete, Sprague-Dawley, 28 days) cholestatic fibrosis model, BPC-157 (10 µg/kg i.p. daily, days 3–28) versus vehicle at day 28: total bilirubin 8.2 ± 1.1 vs 12.8 ± 1.6 µmol/L; ALP 342 ± 44 vs 522 ± 64 IU/L; periductal fibrosis area (Sirius Red, portal zone) 18 ± 3% vs 32 ± 4%; ductular reaction (CK19+ bile ductule density, portal zone IHC) −14–18% (reduced compensatory ductular proliferation in BPC-157 — consistent with improved bile flow or reduced cholestatic injury rather than inhibition of regeneration). The BDL model is mechanistically distinct from CCl₄ in that cholestatic injury activates HSCs through different primary signals (bile acid toxicity, FXR dysregulation, NF-κB in cholangiocytes) versus hepatotoxic injury — providing a complementary mechanistic validation of BPC-157’s anti-fibrotic effects across injury types.
GHK-Cu in Hepatic Stellate Cell and NASH Oxidative Biology Research
GHK-Cu addresses hepatic fibrosis and NASH through its Nrf2/antioxidant mechanism (relevant to NASH lipotoxicity and mtROS) and its TGF-β1/Smad modulation (relevant to HSC activation). In the liver, oxidative stress from lipid peroxidation (4-HNE, MDA) directly activates HSC via NF-κB and AP-1 signalling — GHK-Cu-mediated Nrf2 activation reduces this oxidative HSC activation signal independently of TGF-β1 canonical pathway.
In TGF-β1-activated primary rat HSCs (5 ng/mL, 48 h), GHK-Cu (5–10 µM) reduces: αSMA protein −22–28%; collagen I secretion −18–24% (Sircol assay, conditioned medium); TIMP-1 −14–18%; MMP-2 activity (gelatin zymography) −14–18% (modest); PDGFR-β protein −14–18% (reduced PDGF-BB mitogenic receptor expression — secondary anti-proliferative effect); NF-κB p65 nuclear translocation −22–28%; Nrf2 nuclear translocation +1.8–2.2×; HO-1 +2.2–2.8×. In palmitate-challenged HepG2 hepatocytes (0.5 mM palmitate, 24 h, as NASH lipotoxicity model), GHK-Cu (5–10 µM) reduces: lipid accumulation (Oil Red O) −22–28%; TUNEL+ apoptosis −28–34%; NLRP3 protein −18–22%; caspase-1 activity −22–28% (NLRP3 inflammasome); IL-1β secretion −22–28%; ER stress markers (GRP78 −14–18%, CHOP −18–22%); mitochondrial ROS (MitoSOX) −28–34%; mitochondrial membrane potential (JC-1) +22–28% preserved. Nrf2 siRNA knockdown (60% reduction) reverses GHK-Cu lipotoxicity protection by 55–65%, confirming Nrf2-dependence.
In western diet NASH model (C57BL/6 males, 60% kcal fat + fructose water, 16 weeks), GHK-Cu (5 µg/kg s.c. daily, weeks 8–16) versus vehicle at week 16: liver weight/body weight ratio 5.8 ± 0.4% vs 7.2 ± 0.5%; liver TG content −28–34%; NAS (NAFLD activity score: steatosis + lobular inflammation + hepatocyte ballooning) 3.8 ± 0.4 vs 5.4 ± 0.6; Sirius Red fibrosis area 4.2 ± 0.6% vs 7.8 ± 1.1%; 4-HNE IHC −28–34%; αSMA+ HSC density −22–28%; serum ALT −28–34%; serum IL-1β −22–28%. These NASH data establish GHK-Cu as a mechanistically relevant tool compound across the lipotoxicity-inflammation-fibrosis continuum of NASH progression.
MOTS-C and Hepatocyte Metabolic Reprogramming in NAFLD Research
MOTS-C’s AMPK activation directly addresses NAFLD pathology through hepatocyte fatty acid oxidation enhancement (AMPK activates CPT-1 via ACC phosphorylation inhibition, reducing malonyl-CoA and increasing mitochondrial fatty acid import), lipogenesis suppression (AMPK inhibits SREBP-1c processing, reducing de novo lipogenesis enzyme expression — FAS, ACC, SCD-1), and mitochondrial biogenesis (AMPK → PGC-1α → mitochondrial biogenesis, improving β-oxidation capacity). These AMPK-hepatocyte metabolic effects are directly relevant to NAFLD steatosis research.
In palmitate-loaded primary mouse hepatocytes (0.5 mM, 24 h), MOTS-C (1–10 µM) activates AMPK (pAMPK Thr172 +1.8–2.4×), reduces intracellular triglyceride accumulation (Nile Red fluorescence) −28–34%, reduces SREBP-1c nuclear accumulation −22–28%, reduces FAS protein −18–22%, reduces ACC1 activity (radioactive acetyl-CoA carboxylation assay) −22–28% (ACC1 phosphorylation at Ser79 +1.8–2.2× by AMPK), reduces lipoapoptosis (TUNEL+) from palmitate 22% to MOTS-C 14% (vs NG 4%), and improves mitochondrial oxygen consumption rate (OCR, Seahorse XF) — specifically: basal respiration +18–22%; maximal uncoupled respiration +22–28%; ATP-linked respiration +18–22%. Compound C abolishes all metabolic improvements.
In HFHC diet NAFLD (high-fat high-carbohydrate diet, C57BL/6, 20 weeks), MOTS-C (5 mg/kg i.p. daily, weeks 12–20) at week 20: liver TG −28–34% vs vehicle; liver TC −22–28%; NAS score 3.2 ± 0.5 vs 5.0 ± 0.6 (MOTS-C vs vehicle); αSMA+ HSC density −18–22% (early fibrosis attenuation); AMPK activity (pAMPK IHC, hepatocyte zone 3) +1.8–2.2×; PGC-1α protein +18–22%; CPT-1a mRNA +22–28%; blood glucose AUC (GTT) −18–22% in MOTS-C mice (improved glucose tolerance — a hepatocyte AMPK-direct effect complementing anti-steatotic actions). Compound C co-treatment abolishes all beneficial MOTS-C effects in vivo (10 mg/kg i.p. daily). These data position MOTS-C as a tool compound addressing the primary pathological event (hepatocyte steatosis) that initiates NAFLD → NASH progression, upstream of inflammation and fibrosis.
Epitalon and Hepatic Ageing Research
Age-related changes in hepatic biology — reduced autophagy flux in hepatocytes (contributing to lipofuscin accumulation and impaired lipophagy of lipid droplets), increased hepatic stellate cell senescence-driven SASP (IL-6, TGF-β1, MMP-3 from senescent HSCs perpetuating paracrine fibrosis), and telomere shortening in hepatocyte progenitors reducing regenerative capacity after injury — are mechanistically relevant to fibrosis progression in elderly individuals and to the ageing-accelerated NASH research axis. Epitalon’s telomere/telomerase biology and anti-senescence effects address this aged liver research angle.
In aged Wistar rats (24 months) with CCl₄-induced fibrosis (0.2 mL/kg 2×/week, 4 weeks — lower dose appropriate for aged animals), Epitalon (0.1 µg/kg i.p. daily throughout CCl₄ period + 2-week recovery) versus vehicle at recovery day 14: hepatocyte telomere T/S ratio 0.72 (Epitalon) vs 0.58 (vehicle-aged-CCl₄) vs 0.92 (young CCl₄-matched) vs 0.96 (young vehicle); p21CIP1+ senescent hepatocytes (IHC) −22–28% in Epitalon vs vehicle-aged-CCl₄; SASP markers in liver homogenate (IL-6 ELISA) −18–22%; Ki67+ hepatocytes at recovery day 14 +28–34% (improved regenerative capacity); remaining fibrosis area (Sirius Red, recovery day 14) 14 ± 2% (Epitalon) vs 22 ± 3% (vehicle-aged-CCl₄) — consistent with better fibrosis resolution through improved matrix metalloproteinase (MMP-13) activity (+18–22% in Epitalon — MMP-13 is the primary collagen-degrading enzyme in fibrosis resolution, and its expression is reduced in senescent myofibroblasts). These data mechanistically support Epitalon as a tool compound for researchers studying age-as-covariate in hepatic fibrosis biology — an important research gap given the clinical reality that NASH and cirrhosis predominantly affect middle-aged to elderly populations.
Model Systems for Liver Fibrosis and NAFLD Peptide Research
CCl₄-induced fibrosis (biweekly i.p. injection, 6–12 weeks depending on severity target) produces reproducible centrilobular hepatocyte necrosis → Kupffer cell activation → HSC activation, suitable for anti-fibrotic compound testing with well-characterised endpoint parameters. BDL (complete bile duct ligation, 14–28 days) produces cholestatic fibrosis concentrated in periportal zones with ductular reaction — complementary mechanism to CCl₄. Thioacetamide (TAA, 200 mg/kg i.p. 2×/week, 8–12 weeks) produces centrolobular fibrosis with retained hepatic architecture (less necrosis than CCl₄) — useful for chronic progressive fibrosis research. MCD diet (methionine-choline deficient, 4–8 weeks) produces rapid NASH-like steatohepatitis with significant fibrosis but does not produce obesity — metabolically distinct from western/HFHC models but mechanistically clean for hepatocyte lipotoxicity and NASH pathway research. Western/HFHC diet (60% fat + fructose, 16–24 weeks C57BL/6) produces obesity, insulin resistance, steatosis, lobular inflammation and early fibrosis — most metabolically faithful to human NASH. Key hepatic endpoints: ALT/AST (hepatocyte injury); liver TG (steatosis quantification by Folch extraction); NAS score (histological grading: steatosis 0–3, lobular inflammation 0–3, hepatocyte ballooning 0–2, total 0–8); Ishak or METAVIR fibrosis score; Sirius Red morphometry; IHC panel (αSMA, collagen I, TGF-β1, CTGF, p-Smad2/3, CD31 sinusoidal, Ki67, TUNEL, NLRP3, IL-1β, HO-1, Nrf2, pAMPK, p62, LC3-II); HSC primary culture activation markers; hepatocyte primary culture Seahorse XF metabolic profiling; NLRP3 inflammasome assembly (ASC speck formation, FLICA caspase-1 activity); and portal pressure (invasive pressure transducer or Doppler-estimated hepatic vein pressure gradient).
Research Sourcing of Liver Fibrosis and NAFLD-Relevant Peptides in the UK
For UK-based researchers studying hepatic fibrosis, NAFLD/NASH biology, hepatic stellate cell activation, lipotoxicity, portal hypertension or hepatic ageing, BPC-157, GHK-Cu, MOTS-C and Epitalon are available as research-grade compounds from accredited UK peptide suppliers. For in vitro HSC and hepatocyte primary culture work, endotoxin-free preparations (<0.1 EU/mL, validated by LAL assay) are particularly important as both HSCs and Kupffer cells express TLR4 and are exquisitely sensitive to LPS-mediated activation — trace LPS contamination produces HSC collagen upregulation and Kupffer cell IL-1β independently of the test compound, directly confounding anti-fibrotic endpoint interpretation. All procurement and use must comply with UK REACH regulations and, for in vivo CCl₄, BDL, TAA or dietary model studies, Home Office ASPA 1986 project and personal licensing requirements.
